Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide + ADT Combined With Low-dose Docetaxel in mHSPC
NCT07503379Phase 2Recruiting
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of darolutamide, docetaxel in prostate cancer (PCa). Started Apr 2026; status: recruiting.
02
Drugs
darolutamidedocetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07503379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07503379.